Repros Therapeutics (RPRX) Product Candidate FDA-Review Time
Post# of 35
Posted On: 04/02/2015 4:39:41 AM
Shares of Repros Therapeutics Inc. (RPRX) soared more than 20% Wednesday in extended-hours trading after the company said that the New Drug Application (NDA) for its enclomiphene citrate product candidate has been accepted by the U.S. Food and Drug Administration (FDA), indicating that the application is sufficiently complete to permit a substantive review.
The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.
RPRX is developing this product candidate, formerly known as Androxal(R), for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.
RPRX focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders
More about Repros Therapeutics Inc. (RPRX) at www.reprosrx.com
**
After the closing bell on Wednesday, Micron Technology, Inc. (MU) delivered better-than-expected numbers in its quarterly financial results.
For its second quarter fiscal 2015, MU posted revenues of $4.17 billion, a 1% increase year over year, and non-GAAP net income of $941 million, or $0.81 per diluted share, topping the Capital IQ Consensus Estimate of $0.72 earnings per share on revenues of $4.15 billion for the period
MU is a global leader in advanced semiconductor systems. MU‘s broad portfolio of high-performance memory technologies—including DRAM, NAND and NOR Flash—is the basis for solid state drives, modules, multichip packages and other system solutions.
More about Micron Technology, Inc. (MU) at www.micron.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Chino, CA ( www.chino.crwe-pr.com ) into the CRWE Network.
Chino is located in San Bernardino County, California, about 35 miles east of Los Angeles and 25 miles northeast of Anaheim.
The City of Chino had an estimated population in 2013 (U.S. Census Bureau) of 80,988, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s division CRWE Tube ( www.crwetube.com ) is expected to be integrated in all the CRWE Network
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.
RPRX is developing this product candidate, formerly known as Androxal(R), for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.
RPRX focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders
More about Repros Therapeutics Inc. (RPRX) at www.reprosrx.com
**
After the closing bell on Wednesday, Micron Technology, Inc. (MU) delivered better-than-expected numbers in its quarterly financial results.
For its second quarter fiscal 2015, MU posted revenues of $4.17 billion, a 1% increase year over year, and non-GAAP net income of $941 million, or $0.81 per diluted share, topping the Capital IQ Consensus Estimate of $0.72 earnings per share on revenues of $4.15 billion for the period
MU is a global leader in advanced semiconductor systems. MU‘s broad portfolio of high-performance memory technologies—including DRAM, NAND and NOR Flash—is the basis for solid state drives, modules, multichip packages and other system solutions.
More about Micron Technology, Inc. (MU) at www.micron.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Chino, CA ( www.chino.crwe-pr.com ) into the CRWE Network.
Chino is located in San Bernardino County, California, about 35 miles east of Los Angeles and 25 miles northeast of Anaheim.
The City of Chino had an estimated population in 2013 (U.S. Census Bureau) of 80,988, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s division CRWE Tube ( www.crwetube.com ) is expected to be integrated in all the CRWE Network
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)Repros Therapeutics Inc. (RPRX) Stock Research Links
Scroll down for more posts ▼